Trial Profile
A phase I randomized, double-blind, dose-escalation study of OATD-01
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 04 Oct 2022
Price :
$35
*
At a glance
- Drugs OATD-01 (Primary)
- Indications Asthma; Chronic obstructive pulmonary disease; Idiopathic pulmonary fibrosis; Sarcoidosis
- Focus Adverse reactions; First in man
- Sponsors Molecure; OncoArendi Therapeutics
- 28 Mar 2022 According to Molecure company website OncoArendi has changed its name to Molecure.
- 19 Sep 2018 Status changed to completed, according to the results presented at the 28th Annual Congress of the European Respiratory Society
- 19 Sep 2018 Results presented at the 28th Annual Congress of the European Respiratory Society